Swedencare. Presentation CEO Håkan Lagerberg CFO Jenny Graflind

Size: px
Start display at page:

Download "Swedencare. Presentation CEO Håkan Lagerberg CFO Jenny Graflind"

Transcription

1 Swedencare Presentation CEO Håkan Lagerberg CFO Jenny Graflind

2 Swedencare Summary An Animal Health care company with global presence in a fast growing market Sales in 50 countries, both with fully owned subsidiaries and external distributors ProDen PlaqueOff a world leading product within oral care complemented by a wide range of nutraceuticals (NutriScience) Own production facility on Ireland with a wide product offering A fragmented market continued expansion through acquisitions High growth and profitability Listed On NASDAQ First North since 14 June 2016

3 Company Timeline 1990 s Research & discovery of advantages of product 2001 Swedencare start selling within the Nordic 2006 Patents in Europe and USA are registered 2016 (January) Swedencare acquire former distributors in France, UK and USA 2016 (July) Swedencare acquire Biodistra AB 2017 (March) Production of PlaqueOff in own factory in Ireland 2000 Establishment of current business of Swedencare 2005 International expansion in Europe is launched 2015 New Business Plan developed with new owners 2016 (June) Company is listed on Nasdaq First North 2016 (November) Swedencare acquire the Irish company NutriScience (Ecuphar Ltd.)

4 DOG CAT HORSE ACCESSORIES NUTRACEUTICALS FEED PRESCRIBED PRODUCTS

5 Swedencare and the World Headcount: Swedencare AB: 6 Biodistra: 1 SDC Distribution: 1 Swedencare UK: 6 Swedencare Ireland: 12 Swedencare US: 4 Swedencare Buccosanté: million pets in the U.S. Nutraceuticals, 2500 MUSD in Europe and USA Growth 10 15% per year Pet market in China grows by double digits. Both by number of pets and spending

6 Strategy in three parts Distribution Product Portfolio and Channels Marketing 5 Sales Offices >25 distributors Sales in 50 countries PlaqueOff NutriScience New products Vet Pet retail Pharmacies Retail *B2C and B2B Exhibitions *Distributor support *Training *Digital

7 Pets from something you own to a member of the family * 94% sees the pet as a family member The pets live longer age related symptoms increase Increased demand for organic feed and nutraceuticals Demand of premium products grows *46% of the pet owners have bought a nutraceutical at least once *) USA

8 PlaqueOff a leading oral health product Systemic effect on Oral Health Patent- and Trade mark protected in all our major markets Several clinical studies Marketed in several sizes and forms powder, Dental Bites, Dental Bone, in feed ( fall 2017) pots equates to the yearly consumption for 0,5 million dogs/cats 1,2% of all registered dogs/cats in the USA, Europe, China and Japan Retail value, over 35 MUSD

9 Clinical Studies VOHC The difference between the placebo product and the tested product (ProDen PlaqueOff ) was 30-70% P1 Placebo P2 ProDen PlaqueOff

10 New products 2017 NutriScience by Swedencare for dogs and cats A new group of products within several focus areas for dogs and cats. o Joints and mobility o Skin and coat o Multivitamin supplement o Calming supplement NutriScience by Swedencare for horses We are expanding the selection and we are now able to offer products which also soothes and prevents common problems with horses. o Digestive supplement o For a healthy stomach o For strength and performance o Cooling gel o Salt replacement

11 H1 Main Events Integrate Swedencare Ireland and our extended organization in the UK and Sweden into our global group Design and develop a Swedencare line of NutriScience-products for sales within the pet health care group Launch in Nordics Q Continue with focused marketing activities in Asia, especially in China and South Korea Launching of our new Dental Care Bones in the US market with better than expected demand Launching in Europe Q ERP-system change in Ireland Preparation of launching of feed Fall 2017

12 Key Performance Indicators H1 REVENUE Tkr EBITDA Tkr 25,6% SOLVENCY 66,7 % CHANGE IN REVENUES 64 % NET INCOME Tkr

13 Rolling 4 Quarters - Sales Q Q Q Q Q Q Q Q Q Q Q2 2017

14 Rolling 4 Quarters - EBITDA Q Q Q Q Q Q Q Q Q Q Q2 2017

15 Sales per Product Other 10% Q Q Other 5% PlaqueOff Dental Bites 15% NutriScienc e 28% PlaqueOff Powder 47% PlaqueOff Powder 75% PlaqueOff Dental Bones 12% PlaqueOff Dental Bites 9%

16 Stock Trend Over Time Introduction price: 14 SEK

17 Owners Antal aktier ägarandel Håkan Svanberg & Co Health Care AB ,79% Mastan AB (Håkan Lagerberg genom bolag) ,96% JCC Group Invest Sweden AB (Johan Bergdahl genom bolag) ,96% SEB Life International (Swedia Capital AB) ,08% AMF Aktiefond Småbolag ,79% Walker Crips Weddle Beck PLC ,95% SHB Fonder ,17% Avanza Pension ,39% Timer Hill Europe AG (Martin Shimko - VD Swedencare USA) ,12% ML, Pierce Fenner & Smith Inc ,41% BNP PARIBAS (Hans Persson - VD Swedencare Frankrike) ,27% KBC Securities (Ecuphar NV) ,24% Tedcap AB (Thomas Eklund genom bolag) ,20% Nordnet Pensionsförsäkring AB ,07% Grandeur, Fund BBHBOS ,01% Lin Micka ,96% Staffan Johansson ,86% Per Malmström Consulting AB ,76% Anders Lönner ,69% Granit Fonder Småbolag ,63% Övriga ,69% Totalt ,00%

18 Priorities in H2 Dental Care Bones Expanding NutriScience range China launch Co-ops with feed partners Review acquisition opportunities Digital presence and marketing support Further strengthen partnerships with major players in Vet- and Pet Specialty retailers

19 Financial Strategy long term 250 Sales Forecast Trend Budget 2017: 80M H Rolling 4 Qrts: 70M

20 Why invest in/choose Interesting market segment Growing market with high potential Well known trademark Unique worldwide distribution network Significant growth & impressive margins Strong interest from institutional investors

Q Investor Kit JANUARY-JUNE 2013

Q Investor Kit JANUARY-JUNE 2013 Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference

VITROLIFE AB (PUBL) Pareto Securities Health Care Conference VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

Q Investor Kit JANUARY-MARCH 2014

Q Investor Kit JANUARY-MARCH 2014 Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar

VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar 2018-08-16 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION A Swedish

More information

Company presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018

Company presentation. SEB Nordic Seminar Bella Sky, Copenhagen. Carsten Hellmann, President & CEO 9 January 2018 Company presentation SEB Nordic Seminar Bella Sky, Copenhagen Carsten Hellmann, President & CEO 9 January 2018 Allergy: a global disease with a large unmet need >500 million people affected by allergic

More information

Q Investor Kit JANUARY-JUNE 2014

Q Investor Kit JANUARY-JUNE 2014 Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

Q Investor Kit JANUARY-MARCH 2013

Q Investor Kit JANUARY-MARCH 2013 Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Q Investor Kit January December 2014

Q Investor Kit January December 2014 Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January

More information

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018 CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm

More information

Putting ALK on the right growth trajectory

Putting ALK on the right growth trajectory Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large

More information

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018 ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates

More information

Lars Dahlgren. President and CEO

Lars Dahlgren. President and CEO Lars Dahlgren President and CEO 1 Summing up 2013 Sales in line with last year but decreasing profits Sales +1% Operating profit -5% Earnings per share 13.63 SEK (14.33) Financially challenging year but

More information

A GLOBAL LEADER IN PERSONALIZED NUTRITION

A GLOBAL LEADER IN PERSONALIZED NUTRITION A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking

More information

Q2 INVESTOR KIT JANUARY-JUNE 2011

Q2 INVESTOR KIT JANUARY-JUNE 2011 Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist

More information

Investor Presentation

Investor Presentation ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an

More information

For personal use only

For personal use only ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting

More information

A world leader in allergy immunotherapy

A world leader in allergy immunotherapy A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader

More information

Global Dental Implant Market Professional Survey Report 2016

Global Dental Implant Market Professional Survey Report 2016 Report Information More information from: https://www.wiseguyreports.com/reports/529092-global-dental-implant-market-professional-surveyreport-2016 Global Dental Implant Market Professional Survey Report

More information

Walgreens (WAG) Analyst: Juan Fabres Fall 2014

Walgreens (WAG) Analyst: Juan Fabres Fall 2014 Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores

More information

Interim Report 1 January September 2017

Interim Report 1 January September 2017 2014-01-01 2014-12 Interim Report 1 January 2017 30 September 2017 Cantargia AB 556791-6019 Cantargia refers to Cantargia AB (publ), corporate ID number 556791-6019. Clinical trial initiated Highlights

More information

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014

Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014 Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains

More information

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset

More information

More information at

More information at Report Information More information at https://www.htfmarketreport.com/reports/1288313 Global Homeopathic Products Market Professional Survey Report 2018 Report Code: HTF1288313 Pages: 111 Price: 1-User

More information

Harm de Wildt MD TNI

Harm de Wildt MD TNI Harm de Wildt MD TNI Nutreco Capital Markets Day Derbyshire, UK 17 September 1 2013 Agenda 1 2 3 Market overview Animal Nutrition Europe Animal Nutrition strategic priorities Application Solution Centres

More information

Nordea investor meeting. June 18 th, 2018 Kristian Villumsen, EVP Chronic Care

Nordea investor meeting. June 18 th, 2018 Kristian Villumsen, EVP Chronic Care Nordea investor meeting June 18 th, 2018 Kristian Villumsen, EVP Chronic Care Chronic Care represents more than 75% of Coloplast sales and we continue to outgrow the market FY 15/16 Chronic Care Rest of

More information

Investor Presentation

Investor Presentation Investor Presentation Forward Looking Statements The information presented herein may contain projections, predictions, estimates and other forwardlooking statements within the meaning of Section 27A of

More information

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List

More information

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO KAPITALMARKNADSDAG 20 SEPTEMBER 2016 Thomas Axelsson, CEO 1 AGENDA 16.10-16.30 VD har ordet Thomas Axelsson, CEO 16.30-16.50 Clinical relevance of time-lapse Dr. Niels B. Ramsing, Business Unit Time-lapse,

More information

GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008

GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008 GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference CEO GN ReSound, Mike van der Wallen September 3, 2008 GN Store Nord A/S GN GN Store Store Nord Nord Listed Listed company

More information

Investor Presentation

Investor Presentation Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities

More information

Welcome to Galenicum! APRIL, 2013

Welcome to Galenicum! APRIL, 2013 Welcome to Galenicum! APRIL, 2013 Our corporate image comes from the sunrise. Night represents disease, daylight means health and the sunrise stands for overcoming GALENICUM CORPORATE PRESENTATION 3 Who

More information

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf

More information

Q Investor Kit January December 2015

Q Investor Kit January December 2015 Q4 2015 Investor Kit January December 2015 Summary and Overview 2 Q4 and full year 2015: Headline numbers Sales for the full year increased by 9 percent and for the fourth quarter by 5 percent. In local

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.

More information

Universal Biosensors, Inc.

Universal Biosensors, Inc. Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended

More information

H. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011

H. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011 H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts

More information

BALCHEM CORPORATION. Q Investor Relations Presentation

BALCHEM CORPORATION. Q Investor Relations Presentation BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life

More information

For personal use only

For personal use only Sirtex Medical Limited (ASX:SRX) Macquarie Inaugural Annual Emerging Healthcare Conference Mr Gilman Wong, CEO Mr Darren Smith, CFO Dr David Cade, CMO Wednesday, 10 October 2012 Macquarie Securities Group

More information

27 September Interim results for the six months ended 30 June 2018

27 September Interim results for the six months ended 30 June 2018 27 September 2018 Interim results for the six months ended 30 June 2018 Disclaimer 2 Neither this presentation nor any verbal communication shall constitute, or form part of, any offer, invitation or inducement

More information

Südzucker Group Capital market forum Rhine Neckar

Südzucker Group Capital market forum Rhine Neckar Südzucker Group Capital market forum Rhine Neckar Mannheim, 7 November 2017 Thomas Kölbl (CFO) Südzucker Group, page 1 Südzucker Group at a glance Global operating German food group with long-standing

More information

Global Aspergillosis Drugs Market Professional Survey Report 2016

Global Aspergillosis Drugs Market Professional Survey Report 2016 Report Information More information from: https://www.wiseguyreports.com/reports/526011 Global Aspergillosis Drugs Market Professional Survey Report 2016 Report / Search Code: WGR526011 Publish Date: 24

More information

We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target

We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO 1 Safe Harbour Statement The following

More information

DARA Reports Year-End 2012 Financial Results

DARA Reports Year-End 2012 Financial Results April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,

More information

MYOS RENS Technology CEO Joseph Mannello Issues Letter to Shareholders

MYOS RENS Technology CEO Joseph Mannello Issues Letter to Shareholders December 14, 2018 MYOS RENS Technology CEO Joseph Mannello Issues Letter to Shareholders CEDAR KNOLLS, N.J., Dec. 14, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS),

More information

Investor Relations 1Q 2017

Investor Relations 1Q 2017 Investor Relations 1Q 2017 History Leading Authentic Sports Brand Inspired by the Style, Elegance and Passion of our Italian Heritage Founded by FILA brothers in Biella, Italy Established FILA Korea FILA

More information

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014 1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include

More information

DSM Capital Markets Day 2018

DSM Capital Markets Day 2018 DSM Capital Markets Day 2018 Human Nutrition & Health Jeremy Xu President Human Nutrition & Health ROYAL DSM CAPITAL MARKETS DAY LONDON (UK) 20 JUNE 2018 Safe harbor statement This presentation may contain

More information

Distribution Partner Briefing: A Partnership for Profit. Welcome to Smartcool s information package for prospective channel partners.

Distribution Partner Briefing: A Partnership for Profit. Welcome to Smartcool s information package for prospective channel partners. Distribution Partner Briefing: A Partnership for Profit Welcome to Smartcool s information package for prospective channel partners. This publication is intended only as a general guide to assist you in

More information

Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS

Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to

More information

Delivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental

Delivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental Delivering Results POSITIONED FOR GROWTH Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental PAUL GUGGENHEIM CEO, Patterson Dental Former owner and president, Guggenheim Brothers

More information

Global Silica Fume Materials Market Professional Survey Report 2016

Global Silica Fume Materials Market Professional Survey Report 2016 Report Information More information from: https://www.wiseguyreports.com/reports/513942-global-silica-fume-materials-market-professionalsurvey-report-2016 Global Silica Fume Materials Market Professional

More information

Coloplast A/S. Investor presentation 1H 2005/06

Coloplast A/S. Investor presentation 1H 2005/06 Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound

More information

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator

More information

A world leader in allergy immunotherapy. Jefferies Global Healthcare Conference, London : 19 November 2014 : Flemming Pedersen, CFO & EVP

A world leader in allergy immunotherapy. Jefferies Global Healthcare Conference, London : 19 November 2014 : Flemming Pedersen, CFO & EVP A world leader in allergy immunotherapy ALK at a glance Leading allergy immunotherapy (AIT) specialist AIT: Treats the root cause of allergy Products in all areas of AIT ALK has 33% of the global AIT market

More information

Karel Stoschek Director Infant Nutrition. Infant Nutrition

Karel Stoschek Director Infant Nutrition. Infant Nutrition Karel Stoschek Director Infant Nutrition Infant Nutrition Infant Nutrition January to September 70 60 50 40 30 20 10 0 66 52 55 48 32 2010 2011 2012 2013 2014 140 120 100 80 60 40 20 0 123 104 82 59 16

More information

FY2007 Consolidated Financial Overview

FY2007 Consolidated Financial Overview FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking

More information

artnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016

artnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016 Quarterly Interim Statement for the First Quarter of 2016 Quarterly Interim Statement for the First Quarter of 2016 for Table of Contents General Information and Business Activities Economic Development

More information

Shareholder Presentation Annual Meeting 2018

Shareholder Presentation Annual Meeting 2018 Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)

More information

Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010

Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010 Media release Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010 Growth driven by implant volumes, lifted by Bone Level implant range and Roxolid Third quarter (+3%

More information

Stabilized Rice Bran Nutraceuticals & Functional Food The Road to Healthy Aging

Stabilized Rice Bran Nutraceuticals & Functional Food The Road to Healthy Aging Stabilized Rice Bran Nutraceuticals & Functional Food The Road to Healthy Aging By: Salma A. Helal Managing Director; Health Tech for Integrated Health Solutions 2nd MedSpring brokerage and venturing event

More information

Chronic Care Coloplast Meet the Management London 2017 Kristian Villumsen, EVP Chronic Care Edmond Veome, SVP Chronic Care North America

Chronic Care Coloplast Meet the Management London 2017 Kristian Villumsen, EVP Chronic Care Edmond Veome, SVP Chronic Care North America Chronic Care Coloplast Meet the Management London 2017 Kristian Villumsen, EVP Chronic Care Edmond Veome, SVP Chronic Care North America Chronic Care represents more than 75% of Coloplast sales and we

More information

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce

More information

Letter to Shareholders SEMI-ANNUAL REPORT 2008

Letter to Shareholders SEMI-ANNUAL REPORT 2008 Letter to Shareholders SEMI-ANNUAL REPORT 2008 Dear Shareholder You have in your hand the first shareholder letter issued by Nobel Biocare. Thanks to the conversion of Nobel Biocare s bearer shares into

More information

Financial Presentation

Financial Presentation Financial Presentation Certain of the statements that will be made during this meeting, as well as statements contained in our 2006 Annual Report to Shareholders and Annual Report on Form 10-K filed with

More information

William Demant. Jefferies Healthcare Conf. Nov Søren B. Andersson, VP Investor Relations

William Demant. Jefferies Healthcare Conf. Nov Søren B. Andersson, VP Investor Relations William Demant Jefferies Healthcare Conf. Nov. 2017 Søren B. Andersson, VP Investor Relations Agenda General update Key take-aways from November Interim Statement Hearing Devices Outlook 2017 Q&A 2 General

More information

Sirma Group Holding JSC. Consolidated financial statements for the year ending December 31, 2016

Sirma Group Holding JSC. Consolidated financial statements for the year ending December 31, 2016 Sirma Group Holding JSC Consolidated financial statements for the year ending December 31, 216 Changes in share prices for the period ending 31.12.216 Last trading price on 3.12 1.189 BGN Change in share

More information

Agreement to Acquire Spinal Kinetics, Inc. March 15, 2018

Agreement to Acquire Spinal Kinetics, Inc. March 15, 2018 Agreement to Acquire Spinal Kinetics, Inc. 1 March 15, 2018 2 SAFE HARBOR STATEMENT AND USE OF NON GAAP MEASURES WHY SPINAL KINETICS? The Spinal Kinetics M6 artificial discs further round out Orthofix

More information

We want to save patients with severe cancer and autoimmune diseases Entering clinical phase with our lead antibody CAN04 to our proprietary target

We want to save patients with severe cancer and autoimmune diseases Entering clinical phase with our lead antibody CAN04 to our proprietary target We want to save patients with severe cancer and autoimmune diseases Entering clinical phase with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO 1 Safe Harbour Statement The following

More information

DELICA D:5 ACTIVE GEAR 0

DELICA D:5 ACTIVE GEAR 0 DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion

More information

EU5 Bariatric Surgery Procedures Outlook to 2020

EU5 Bariatric Surgery Procedures Outlook to 2020 EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...

More information

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020 BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...

More information

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue

More information

Photocure ASA Executing the Strategy

Photocure ASA Executing the Strategy Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address

More information

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020 Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3

More information

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

An exciting combination in a high growth, high margin Nutrition category. Name of chairman An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views

More information

Global Vitamin Market Professional Survey Report 2016

Global Vitamin Market Professional Survey Report 2016 Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Vitamin Market Professional Survey Report 2016 Global Vitamin Market Professional Survey Report 2016 Publication

More information

For personal use only

For personal use only HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening

More information

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,

More information

Elekta Innovation and Growth. ESTRO 2012 Capital Markets Presentation

Elekta Innovation and Growth. ESTRO 2012 Capital Markets Presentation Elekta Innovation and Growth ESTRO 2012 Capital Markets Presentation 15.00 Introduction Partner in cancer care Growth Tomas Puusepp President and CEO 15.30 Patient-focused development Cancer care solutions

More information

Coloplast A/S. Investor Presentation 2005/06

Coloplast A/S. Investor Presentation 2005/06 Coloplast A/S Investor Presentation 2005/06 2 Coloplast in brief Coloplast s products and services help patients achieve greater independence from medical challenges in 4 areas, ostomy care, urology &

More information

The acquisition of Fortitech

The acquisition of Fortitech The acquisition of Fortitech Accelerating DSM s strategy to become a full solutions provider in food ingredient blends Investor Relations 8 November 2012 Overview Fortitech at a glance Acquisition rationale

More information

To be the partner of choice Straumann

To be the partner of choice Straumann To be the partner of choice Straumann Gilbert Achermann, CEO Helvea Swiss Equities Conference 11 January 2008, Bad Ragaz Table of contents 1. A snapshot of Straumann 2. Financials 3. Markets and opportunities

More information

APPLIANCE TELECOMMUNICATIONS

APPLIANCE TELECOMMUNICATIONS May 2001 1 DEVICE CRT PDP CRT components APPLIANCE Air Conditioner Refrigerator Washing machine Cooking appliance DISPLAY& MEDIA TV / Monitor CD-ROM DVD products VCR / PC / PCB TELECOMMUNICATIONS Switching

More information

Photocure ASA Executing the Strategy

Photocure ASA Executing the Strategy Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events

More information

Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS

Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to DSM s

More information

5 Opportunities in the Nutritional Supplements Industry

5 Opportunities in the Nutritional Supplements Industry 5 Opportunities in the Nutritional Supplements Industry Nutritional supplements play a key role in the lives of U.S. adult consumers interested in health and wellness (H&W). Within this segment, they spend,

More information

SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018

SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report

More information

artnet AG Quarterly Interim Statement for the First Quarter of 2017 artnet AG Quarterly Interim Statement for the First Quarter of 2017

artnet AG Quarterly Interim Statement for the First Quarter of 2017 artnet AG Quarterly Interim Statement for the First Quarter of 2017 Quarterly Interim Statement for the First Quarter of 2017 Quarterly Interim Statement for the First Quarter of 2017 Table of Contents General Information and Business Activities Economic Development of

More information

NASDAQ: FHCO 2016 Annual Meeting

NASDAQ: FHCO 2016 Annual Meeting NASDAQ: FHCO 2016 Annual Meeting Q1 2016 At a Glance NASDAQ Core product FHCO FC2 Female Condom Gross margin ~66% Operating margin ~29% Total current assets $24 million no L/T debt Profitable Starting

More information

Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015

Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 (Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation

More information

Designing a Smoke-Free Future

Designing a Smoke-Free Future Designing a Smoke-Free Future Morgan Stanley Global Consumer & Retail Conference New York, November 14, 2017 Jacek Olczak Chief Financial Officer Martin King President, Asia Region Forward-Looking and

More information

Essential Oil & Aromatherapy Market Research Report- Forecast to 2023

Essential Oil & Aromatherapy Market Research Report- Forecast to 2023 Report Information More information from: https://www.marketresearchfuture.com/reports/3319 Essential Oil & Aromatherapy Market Research Report- Forecast to 2023 Report / Search Code: MRFR/F-B & N/2386-HCRR

More information

Global Dental Implant Market Research Report 2018

Global Dental Implant Market Research Report 2018 Report Information More information from: https://www.wiseguyreports.com/reports/3220035-global-dental-implant-market-research-report-2018 Global Dental Implant Market Research Report 2018 Report / Search

More information

Global Cosmetic Dentistry Market Research Report 2018

Global Cosmetic Dentistry Market Research Report 2018 Report Information More information from: https://www.wiseguyreports.com/reports/3029111-global-cosmetic-dentistry-market-research-report- 2018 Global Cosmetic Dentistry Market Research Report 2018 Report

More information

Closing of Nucletron acquisition Building a stronger position in the cancer care market. September 15, 2011

Closing of Nucletron acquisition Building a stronger position in the cancer care market. September 15, 2011 Closing of Nucletron acquisition Building a stronger position in the cancer care market September 15, 2011 Important step in Elekta s growth strategy Nucletron is the world leader in Brachytherapy and

More information

Coloplast A/S. Investor Presentation Investormøde 16. Januar 2006

Coloplast A/S. Investor Presentation Investormøde 16. Januar 2006 Coloplast A/S Investor Presentation Investormøde 16. Januar 2006 2 Defining Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 5 areas: Ostomy

More information

CEO Operational Report. Annual General Meeting 23 October 2013

CEO Operational Report. Annual General Meeting 23 October 2013 CEO Operational Report Annual General Meeting 23 October 2013 Leading the Field Clinical Trials Axon Sports Cogstate Research COGNIGRAM Playing an integral role in cognition-related clinical trials Cutting

More information

Second Quarter and First Half 2011 Conference Call. 29 July, SORIN GROUP Presentation 1

Second Quarter and First Half 2011 Conference Call. 29 July, SORIN GROUP Presentation 1 Second Quarter and First Half 2011 Conference Call 29 July, 2011 SORIN GROUP Presentation 1 DISCLAIMER This presentation contains management preliminary estimates and forward-looking statements, including

More information

SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB

SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product

More information